PATIENT CHARACTERISTICS AND TREATMENT ADHERENCE AMONG PATIENTS TREATED WITH DELAYED-RELEASE DIMETHYL FUMARATE FOR RELAPSING REMITTING MULTIPLE SCLEROSIS IN ISRAEL

被引：0
|
作者：
Desai, U. [1 ]
Huang, M. [2 ]
Kirson, N. Y. [1 ]
King, S. [1 ]
Hellstern, M. [1 ]
Schonfeld, S. [1 ]
Birnbaum, H. G. [1 ]
Lee, A. [2 ]
机构：
[1] Anal Grp Inc, Boston, MA USA
[2] Biogen, Cambridge, MA USA
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 05期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND45
引用
收藏
页码：A195 / A195
页数：1
相关论文
共 50 条
  • [41] Dimethyl fumarate in the treatment of relapsing-remitting multiple sclerosis: an overview
    Bomprezzi, Roberto
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2015, 8 (01) : 20 - 30
  • [42] Comparative effectiveness using a matching-adjusted indirect comparison between delayed-release dimethyl fumarate and fingolimod for the treatment of relapsing-remitting multiple sclerosis
    Fox, R. J.
    Cutter, G.
    Chan, A.
    Xiao, J.
    Okwuokenye, M.
    Levison, D.
    Lewin, J. B.
    Edwards, M. R.
    Marantz, J. L.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 530 - 531
  • [43] Efficacy and Safety of Delayed-release Dimethyl Fumarate for Relapsing-remitting Multiple Sclerosis in Prior Interferon Users: An Integrated Analysis of DEFINE and CONFIRM
    Fernandez, Oscar
    Giovannoni, Gavin
    Fox, Robert J.
    Gold, Ralf
    Phillips, J. Theodore
    Potts, James
    Okwuokenye, Macaulay
    Marantz, Jing L.
    CLINICAL THERAPEUTICS, 2017, 39 (08) : 1671 - 1679
  • [44] Incidence and mitigation of gastrointestinal events in patients with relapsing-remitting multiple sclerosis receiving delayed-release dimethyl fumarate: a German phase IV study (TOLERATE)
    Gold, Ralf
    Schlegel, Eugen
    Elias-Hamp, Birte
    Albert, Christian
    Schmidt, Stephan
    Tackenberg, Bjoern
    Xiao, James
    Schaak, Tom
    Salmen, Hans Christian
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2018, 11
  • [45] Delayed-release Dimethyl Fumarate Treatment Shifts the Immune Repertoire in Patients With Relapsing-Remitting Multiple Sclerosis: Results of PROCLAIM, an Open-label Phase 3 Study
    Robertson, Derrick
    Zielinski, Tomasz
    Parks, Becky
    Chen, Chongshu
    Mehta, Devanghi
    Fam, Sami
    Cascione, Mark
    NEUROLOGY, 2019, 92 (15)
  • [46] A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries
    Takahiko Saida
    Takashi Yamamura
    Takayuki Kondo
    Jang Yun
    Minhua Yang
    Jie Li
    Lalitha Mahadavan
    Bing Zhu
    Sarah I. Sheikh
    BMC Neurology, 19
  • [47] A randomized placebo-controlled trial of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis from East Asia and other countries
    Saida, Takahiko
    Yamamura, Takashi
    Kondo, Takayuki
    Yun, Jang
    Yang, Minhua
    Li, Jie
    Mahadavan, Lalitha
    Zhu, Bing
    Sheikh, Sarah I.
    BMC NEUROLOGY, 2019, 19 (1)
  • [48] Safety and efficacy of delayed-release dimethyl fumarate in patients with relapsing-remitting multiple sclerosis: 9 years' follow-up of DEFINE, CONFIRM, and ENDORSE
    Gold, Ralf
    Arnold, Douglas L.
    Bar-Or, Amit
    Fox, Robert J.
    Kappos, Ludwig
    Chen, Chongshu
    Parks, Becky
    Miller, Catherine
    THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2020, 13
  • [49] Risk factors for lymphopenia in patients with relapsing-remitting multiple sclerosis treated with dimethyl fumarate
    Morales, Fabian Sierra
    Koralnik, Igor J.
    Gautam, Shiva
    Samaan, Soleil
    Sloane, Jacob A.
    JOURNAL OF NEUROLOGY, 2020, 267 (01) : 125 - 131
  • [50] Characterization of lymphopenia in relapsing-remitting multiple sclerosis patients treated with dimethyl fumarate and fingolimod
    Nakhaei-Nejad, M.
    Barilla, D.
    Lee, C-H.
    Blevins, G.
    Giuliani, F.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 618 - 618
12345